Lobe Sciences Ltd. — Regulatory Filings 2021

Dec 24, 2021

Note: [01 Mar 2017] – The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative.

FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS – PARTICIPATION FEE

MANAGEMENT CERTIFICATION

==> picture [487 x 532] intentionally omitted <==

----- Start of picture text -----

Brian Zasitko
I, ____ , an officer of the reporting issuer noted below have examined this
Form 13-501F1 (the Form ) being submitted hereunder to the Alberta Securities Commission and
certify that to my knowledge, having exercised reasonable diligence, the information provided in
the Form is complete and accurate.
Brian Zasitko December 23, 2021
____ ____
Name: Date: Brian Zasitko
Title: CFO
Lobe Sciences Ltd.
Reporting Issuer Name:
August 31, 2021
End date of previous financial year:
Type of Reporting Issuer: [ ] Class 1 reporting [ ] Class 3B reporting
issuer issuer
Canadian Securities Exchange
Highest Trading Marketplace:
Market value of listed or quoted equity securities:
LOBE
Equity Symbol
01/09/2020 08/31/2021
1st Specified Trading Period (dd/mm/yy) __ to _____
Closing price of the security in the class or series on the
last trading day of the specified trading period in which
0.065
such security was listed or quoted on the highest trading $ ____
marketplace (i)
----- End of picture text -----

Number of securities in the class or series of such security outstanding at the end of the last trading day of	Number of securities in the class or series of such security outstanding at the end of the last trading day of	______ 224,633,984
the specified trading period		(ii)
	(i) x (ii)	$ ____ 14,601,209
Market value of class or series		(A)
2nd Specified Trading Period(dd/mm/yy)	___ to __
Closing price of the security in the class or series on the
last trading day of the specified trading period in which
such security was listed or quoted on the highest trading		$ ____
marketplace		(iii)
Number of securities in the class or series of such
security outstanding at the end of the last trading day of		____
the specified trading period		(iv)
	(iii) x (iv)	$ ____
Market value of class or series		(B)
3rd Specified Trading Period(dd/mm/yy)	___ to __
Closing price of the security in the class or series on the
last trading day of the specified trading period in which
such security was listed or quoted on the highest trading		$ ____
marketplace		(v)
Number of securities in the class or series of such
security outstanding at the end of the last trading day of		____
the specified trading period		(vi)
	(v) x (vi)	$ ____
Market value of class or series		(C)

4th Specified Trading Period (dd/mm/yy) __ to __ Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading $ ___ marketplace (vii) Number of securities in the class or series of such security outstanding at the end of the last trading day of ___ the specified trading period (viii) (vii) x (viii) $ ___ Market value of class or series (D) 5th Specified Trading Period (dd/mm/yy) __ to __ Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading $ ___ marketplace (ix) Number of securities in the class or series of such security outstanding at the end of the last trading day of ___ the specified trading period (x) (ix) x (x) $ ___ Market value of class or series (E) Average Market Value of Class or Series (Calculate the simple average of the market value of the class or 14,601,209 series of security for each applicable specified trading $ ____ period (i.e. A through E above)) ( 1 )

(Repeat the above calculation for each other class or series of equity securities of the reporting issuer (and a subsidiary, if applicable) that was listed or quoted on a marketplace at the end of the previous financial year)

Fair value of outstanding debt securities:
(Provide details of how value was determined)		$ ____
		(2)
		14,601,209
Capitalization for the previous financial year	(1) + (2)	$ ____
		400
Participation Fee		$ ____
Late Fee, if applicable		$ ____
		400
Total Fee Payable		$ ____
(Participation Fee plus Late Fee)